EXPOSURES Induction chemotherapy and postremission therapy with cytarabine hydrochloride with or without anthracycline, followed by highly HLA-mismatched related or fully mismatched unrelated donor cell infusion. No graft-vs-host disease prophylaxis was used.
O lder patients (≥60 years) with acute myeloid leukemia (AML) have a lower complete remission (CR) rate and higher mortality after standard treatments because of intrinsic drug resistance related to poor-risk cytogenetics as well as unique biology, with different molecular drivers evident compared with younger patients.
1-3 Induction chemotherapy with standard-dose cytarabine hydrochloride in combination with an anthracycline aims at reducing the tumor burden but confers a risk of organ toxicities. Although chemotherapy with attenuated doses decreases organ toxicities, it has reduced ability to kill leukemic cells and is associated with low CR rates and poor short-term survival. 3, 4 Higher doses of daunorubicin hydrochloride result in greater response rates compared with conventional doses, but the benefits in older patients with AML are limited mainly to patients younger than 70 years. [5] [6] [7] Although allogeneic transplant has been used successfully to cure both younger and older patients with AML, it is often limited by the high incidence of nonrelapse mortality (NRM) and severe toxicities, even with nonmyeloablative conditioning or reduced-intensity conditioning regimens.
8-11
Primary clinical studies [12] [13] [14] have shown that infusion of HLA-mismatched donor granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (GPBSCs) combined with chemotherapy (microtransplant [MST] ) increased CR rates, improved survival, and avoided graft-vshost disease (GVHD) in small cohorts of older patients with AML. However, studies involving larger cohorts and multicenter experience with MST in older patients are scarce.
In the present study, we identified 185 patients aged 60 to 85 years with newly diagnosed AML undergoing HLAmismatched MST at 12 centers in China, the United States, and Spain in the Microtransplantation Interest Group. These include the following: (1) Department of Hematology and Transplantation, Affiliated Hospital of The Academy of Military Medical Sciences, Beijing, China; (2) Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Duke Cancer Institute, Durham, North Carolina; (3) Department of Hematology, Jiangsu Province People's Hospital, Nanjing, China; (4) Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Keck School of Medicine of University of Southern California, Los Angeles; (5) Department of Haematology, Hospital Universitario Puerta de Hierro, Majadahonda, Comunidad de Madrid, Spain; (6) Department of Hematology, The Second Artillery General Hospital, Beijing, China; (7) Department of Hematology, He Ping Central Hospital of the Changzhi Medical College, Changzhi, China; (8) Department of Hematology, Central Hospital of Xinxiang City, Xinxiang, China; (9) Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; (10) Department of Hematology, The Fourth Military Medical University, Xi'an, China; (11) Department of Hematology, The Second Affiliated Hospital of Shanxi University, Taiyuan, China; and (12) Department of Hematology, Central Hospital of Hefei City, Hefei, China. The primary end point of the study was to evaluate CR rates, leukemiafree survival (LFS), and overall survival (OS) in different age groups. Additional end points of the study included hematopoietic recovery, GVHD, relapse rate, NRM, and other treatment-related toxic effects. Of the 202 older patients with de novo AML screened, 185 patients were enrolled in the present study, and the other 17 patients were excluded because of patient refusal (n = 3), donor refusal (n = 4), other nonprotocol treatment (n = 9), or death before the first induction chemotherapy (n = 1). The 185 included patients were divided into the following 4 age groups: 60 to 64 years, 65 to 69 years, 70 to 74 years, and 75 to 85 years. Among the 185 patients, 24 were included in a previous study, 12 but updated data were added to the present study. Another 6
Methods

Patients and Donors
Key Points
Question Can microtransplant improve outcomes in older patients with acute myeloid leukemia?
Findings In a multicenter clinical study among 185 patients with de novo acute myeloid leukemia at 12 centers in China, the United States, and Spain, the overall complete remission rate was 74.6% among patients aged 60 to 85 years; the 1-year overall survival rates were 77.8% to 87.7% among patients grouped in 5-year age increments between 60 and 74 years, which were much higher than the rate among patients aged 75 to 85 years (51.7%). The nonrelapse mortality and graft-vs-host disease rates were 10.1% and 1.1%, respectively, among the entire cohort aged 60 to 85 years.
Meaning As a novel transplantation technique, microtransplant provides an effective and safe therapy for older patients with acute myeloid leukemia.
patients were excluded from this study because of age older than 85 years (n = 2) or enrollment outside of the study period (n = 4).
The study protocol, including inclusion and exclusion criteria and protocol implementation, was approved by the Human Ethics Committee of the Affiliated Hospital of The Academy of Military Medical Sciences and at each study site and was in accord with the Declaration of Helsinki. All patients and their donors provided written informed consent before the study. The patients were treated according to preregistered protocols.
Treatment Design
Induction Chemotherapy Induction chemotherapy mainly consisted of daunorubicin hydrochloride (45-60 mg/m 2 ), mitoxantrone hydrochloride followed by an infusion of GPBSCs 24 hours (day 0) after the completion of cytarabine. If the patients failed to achieve CR after the first cycle of induction chemotherapy, a second cycle of the same induction chemotherapy was permitted.
Postremission Therapy
Patients who achieved CR received 2 to 3 courses of MST as postremission therapy, which consisted of intermediate-dose cytarabine (1.0 g/m 2 for 6 doses) (n = 125) or DAAG chemotherapy (n = 13), followed by an infusion of GPBSCs after cytarabine chemotherapy, with up to 3-month intervals between the courses. None of the patients received any GVHD prophylaxis or further maintenance therapy. Infection prophylaxis and support treatment, including G-CSF, were administered according to each institution's standard practice guidelines. A recommended dose adjustment was followed. For patients with a creatinine clearance rate decreasing to less than 60 mL/min/1.73 m 2 (to convert creatinine clearance rate to milliliters per second per meter squared, multiply by 0.0167) or for those in the third and fourth age groups, the doses of daunorubicin and cytarabine were reduced to 2 days and 5 days, respectively, during induction chemotherapy, and the dose of cytarabine was reduced to 500 mg/m 2 for 6 doses during postremission therapy.
Apheresis of Donor Peripheral Mononuclear Cells
Mobilization and apheresis of HLA-mismatched donor peripheral mononuclear cells were performed as previously described. 12 Fresh donor cells were used in the first induction chemotherapy, and other donor cells were divided into small packs and cryopreserved in liquid nitrogen for second induction chemotherapy or postremission therapy.
Before transplant, the donor and recipient HLA-A (OMIM 142800), HLA-B (OMIM 142830), HLA-C (OMIM 142840), HLA-DRB1 (OMIM 142857), and HLA-DQB1 (OMIM 604305) alleles were genotyped using the polymerase chain reactionsequence-specific primer method. For patient and donor pairs who had more related and matched HLA loci, matched red blood cell type and cytomegalovirus-seronegative donors were chosen first; however, donor sex and other characteristics were not considered a priority. If patients had no available related donor, an HLA-mismatched unrelated donor was used.
Detection of Donor Chimerism and Microchimerism
Full donor chimerism and mixed chimerism were detected by short tandem repeat-polymerase chain reaction assay as previously described.
12,19 For microchimerism detection (donor cells <1%), only 26 female patients who had a male donor and sufficient samples were monitored as previously described.
12,19
Response Criteria and Outcome Evaluation Acute GVHD and chronic GVHD were defined according to published criteria. 20, 21 Monitoring for relapse was performed according to institutional guidelines. The median relapse time was defined as the median time from CR to relapse. Early death was defined as death within 4 weeks after initiation of induction chemotherapy.
Statistical Analysis
Variables related to clinical characteristics between age groups were compared using χ 2 test. Survival data were analyzed by the log-rank test, and survival curves were prepared using the Kaplan-Meier method. Cox proportional hazards regression models were applied to evaluate the relative factors for LFS, OS, NRM, and relapse. The denominators in adjusted percentages in OS, LFS, relapse, and NRM are not the sample proportions of observations. Statistical significance was defined as 2-sided P < .05. A software program (SPSS, version 17.0; SPSS Inc) was used in all statistical analyses.
Results
Patient Characteristics
Among 185 patients with de novo AML at 12 centers in China, the United States, and Spain, the median age was 67 years (age range, 60-85 years), and 75 (40.5%) were female. eTable 1 in the Supplement lists demographic and disease characteristics before transplant, stratified by age group. There were no statistically significant differences among the 4 age groups except for the donor and recipient HLA-mismatched loci; the fourth age group had fewer patients but many more donors and recipients with HLA-mismatched loci 7 through 10 compared with the other age groups.
Response to Induction Chemotherapy 
Hematopoietic Recovery and Toxicity
The median times to neutrophil and platelet recovery were 12 days and 14 days after induction chemotherapy, respectively, with no significant differences among the 4 age groups. The overall rates of severe infection and organ failure were 8.0% (11 of 138) and 2.2% (3 of 138), respectively, with no significant differences among the 4 age groups. The median follow-up time was 14 months (range, 1-106 months). The median OS times were 16, 14, 13, and 10 months in the 4 age groups. The 1-year OS rate was much lower in the fourth age group (51.7%) than rates in the first 3 age groups (87.7%, P = .004, 85.8%, P = .008, and 77.8%, P = .04, respectively) ( Figure 1A) . The 2-year OS rate was 63.7% in the first age group, which was higher than the rates in the third (34.2%) (P = .02) and fourth (14.8%) (P < .001) groups. Similarly, the second age group also had higher 2-year OS rate (66.8%) compared to the third (P = .03) and fourth (P < .001) age groups.
OS and LFS
The overall 1-year LFS rate was 64.9% in the first age group, which was much higher than the rates in the third (35.4%) (P = .02) and the fourth (21.7%) (P = .003) age groups. Similarly, the second age group also had much higher 1-year LFS rate (73.8%) compared to the third (P = .01) and fourth (P = .002) age groups ( Figure 2A) . The 2-year LFS rate was 51.0% in the first age group, which was much higher than the rates in the third (25.3%) (P = .02) and the fourth (14.5%) (P = .002) age groups. Similarly, the second age group also had much higher 2-year LFS rate (59.1%) compared to the third (P = .009) and fourth (P = .001) age groups.
NRM and Relapse
The median relapse time was 8.5 months (range, 1.5-62 months). The 1-year cumulative incidence of relapse in the first age group (23.2%) was much lower than the rates in the third (58.2%) (P = .001) and the fourth (69.0%) (P = .002) age groups. Similarly, the second age group also had much lower 1-year cumulative incidence of relapse (22.9%) compared to the third (P =.02) and fourth (P = .03) age groups. There was no significant difference in the 2-year cumulative incidences of relapse between the first 2 age groups (39.7% and 32.5%) (P = .99), however, the third age group had much higher 2-year incidence of relapse (70.1%) compared to the first (P = .001) and second (P = .01) age groups.
Similarly, the fourth age group also had much higher 2-year incidence of relapse (79.3%) compared to the first (P = .001) and second (P = .02) age groups ( Figure 3A) . A, Overall survival of the patients according to 4 age groups. B, Patients who received 2 or 3 courses of postremission therapy had much higher 2-year overall survival compared with those who received one course or none. C, Patients in the high-risk group had lower 2-year overall survival compared with the standard-risk group. del Indicates deleted.
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The overall NRM was 10.1%. The 100-day cumulative incidences of NRM were 1.9%, 0%, 0%, and 5.6%, with no significant differences among the 4 age groups. The 1-year cumulative incidences of NRM were 8.1% in all patients aged 60 to 85 years and 10.2%, 0%, 3.4%, and 26.0% in the A, Relapse incidence of the patients according to 4 age groups. B, Patients who received 2 or 3 courses of postremission therapy had much lower relapse rates compared with those who received one course or none. C. Patients in the high-risk group had a higher relapse rate compared with the standard-risk group. del Indicates deleted.
Research Original Investigation
HLA-Mismatched Microtransplant in Patients Newly Diagnosed With Acute Myeloid Leukemia 4 age groups, with no significant differences between the first and fourth age groups. The 2-year cumulative incidences of NRM were also comparable among the 4 age groups (17.2% vs 7.7% vs 12.2% vs 26.0% (P = .06) ( Figure 4A ).
Donor Chimerism and Microchimerism
Of the 185 patients, 2.7% (5 of 185) established full or mixed chimerism. Only 2 patients demonstrated stable full donor chimerism, and 3 patients developed mixed chimerism. Of the 26 patients who had an informative SRY (OMIM 480000) gene, 8 (30.8%) developed donor microchimerism, with a range of 0.0000151 to 0.0989 copies of gene expression. Assessed kinetics of donor microchimerism showed that microchimerism emerged on day 2 and reached its peak on days 7 to 10 after the MST treatment. Among the 8 patients, the donor microchimerism remained for longer than 10 months in 1 patient, longer than 6 months in 2 patients, and longer than 2 months in 1 patient and remained for shorter than 2 weeks in 4 patients.
Graft-vs-Host Disease
Only 2 patients (1.1%) were diagnosed as having severe acute GVHD because of high fever, location of rash on the neck, and severe hyperbilirubinemia after neutrophil recovery and transient full donor engraftment after MST (biopsies were not performed). The patients failed to respond to anti-GVHD treatment and died of multiorgan failure at days 36 and 39, respectively, after MST. No definite clinical acute or chronic GVHD was observed in any other patients.
Multivariable Analysis
On multivariable analysis of the factors influencing LFS, OS, and relapse, such as patient and donor age, sex, HLAmismatching loci, related or unrelated donor, infused CD34 Figure 3B ) compared with those who received one course or none (11.1%, P < .001, 7.8%, P < .001, and 89.4%, P < .001, respectively), although there was no significant difference in 100-day NRM (1.0% vs 2.6%) (P = .50) and 1-year NRM (6.4% vs 13.5%) (P = .21) ( Figure 4B ). Similarly, patients in the high-risk group had lower 2-year OS (34.3% [31 of 60]) (P = .004) ( Figure 1C ) and LFS (28.5% [26 of 60]) (P = .007) ( Figure 2C ) but a slightly higher relapse rate (61.5% [22 of 60]) (P = .21) ( Figure 3C) 
Discussion
The present study reports long-term outcomes among 185 patients aged 60 to 85 years with newly diagnosed AML who received HLA-mismatched MST in multiple centers from the Microtransplantation Interest Group. The overall CR rate was 74.6% (138 of 185), and OS rates at 1 year and 2 years were 79.9% and 50.2%, respectively (eTable 2 in the Supplement), suggesting encouraging therapeutic results, with a higher CR rate and longer survival compared with standard care in older patients. 19, 22, 23 It has been demonstrated that the major reasons for initial treatment failure in older patients with AML are the high early mortality and delayed hematopoietic recovery. [3] [4] [5] [6] [7] 22, 23 In a report from a Swedish population registry that included 3371 patients with AML, CR rates among intensively treated patients were found to decrease with age. While MST achieved a high CR rate and 1-year survival in 4 age groups, the leukemia relapse rate was much higher, especially for the patients aged 75 to 85 years, who are considered "very old" patients with AML. Unlike the other age groups, these patients received a reduced chemotherapy dose, and half of them completed either one postremission course or none. Overall 1-year and 2-year relapse rates were 69.0% and 79.3%, respectively, among the very old patients, which were much higher compared with the other age groups, although 100-day NRM (5.6%) was comparable to rates of the other age groups. Otherwise, the patients who received 2 or 3 courses of postremission therapy had a much higher 2-year OS (61.3% vs 11.1%) (P < .001) and lower relapse rate (39.7% vs 89.4%) (P < .001) than those who received one course or none. These data suggest that the main reasons for high relapse rates in very old patients with AML may be related to lack of sufficient postremission therapy as well as reduced chemotherapy dose. Therefore, reducing postremission therapy courses or chemotherapy dose simply because of patient age may not be advisable for older patients.
Studies [6] [7] [8] [9] [29] [30] [31] [32] [33] have shown that most patients with AML could achieve full donor chimerism or convert to full donor chimerism from mixed chimerism after hematopoietic stem cell transplant; however, severe GVHD remained a major complication, particularly in HLA-mismatched transplant. In the present MST study, 2.7% (5 of 185) and 30.8% (8 of 26) of patients developed full or mixed chimerism and microchimerism, respectively, because no lymphoablative conditioning was used. Notably, only 2 patients (1.1%) developed severe acute GVHD, although all patients received cell infusions from HLA-mismatched donors, including 9 with unrelated and 0 of 10 HLA-matched unrelated donors, and no GVHD prophylaxis was used. The extremely low GVHD incidence contributed significantly to reducing NRM and improving survival.
29-35
Limitations A limitation of this study is the absence of randomized groups, such as reduced-intensity or nonmyeloablative conditioning transplant recipients, although a randomized clinical trial would be much more difficult to implement in older patients, especially for those older than 75 years. A prospective, randomized, phase 3 confirmatory study comparing this approach with chemotherapy only is also under way by the International Microtransplantation Cooperative Group.
Conclusions
Clinical results suggest that MST is a safe, practical, and reproducible therapy in older patients newly diagnosed as having AML. Our findings showed that this approach achieved high CR rates in patients with AML aged 60 to 85 years and higher 1-year OS in those aged 60 to 74 years. 14(10.1) 7(13.5) 1(3.0) 2(5.9) 4(21.1) P=0.063 100-day NRM, n(%) 2(1.5) 1(1.9) 0(0) 0(0) 1(5.6) P=0.375 1-year NRM, n(%) 10(8.1) 5(10.2) 0(0) 1(3.4) 4(26.0) P=0.017 2-year NRM, n(%) 14(15.3) 7(17.2) 1(7.7) 2(12.2) 4(26.0) P=0.063
Abbreviations: MNC, mononuclear cells; MA, mitoxantrone plus cytarabine; DA, daunorubicin plus cytarabine; IA, idarubicin plus cytarabine; DAAG, decitabine, cytarabine, aclarubicin plus granulocyte colony stimulating factor; CR, complete remission; OS, overall survival; LFS, leukemia-free survival; NRM, non-relapse mortality.
